Table 5.
Serum lipid profiles of the Kochujang and placebo groups at the 0-wk and at 12-wk of the study
|
Parameters |
Kochujang group (n=30) |
Placebo group (n=30) |
|
|
|
|
||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0wk | 12wk | Change* | 0wk | 12wk | Change* | P value1 | P value2 | P value3 | P value41 | |
| Total cholesterol(mg/dL) |
193.4±5.1 |
189.8±5.9 |
-3.6±3.9 |
196.4±6.3 |
197.9±5.1 |
1.5±4.2 |
0.378 |
0.047 |
0.740 |
0.367 |
|
Triglycerides(mg/dL) |
112.5±9.1 |
94.6±5.8† |
-17.9±8.5 |
125.6±12.7 |
139.1±13.8 |
13.5±12.9 |
0.049 |
0.412 |
0.026 |
0.042 |
| HDL (mg/dL) |
52.3±1.9 |
51.2±1.9 |
-1.07±1.5 |
52.3±2.2 |
50.9±1.8 |
-1.32±1.7 |
0.912 |
0.100 |
0.923 |
0.670 |
| LDL (mg/dL)) |
124.9±4.7 |
122.3±5.2 |
-0.25±0.14 |
125.9±6.1 |
123.6±5.3 |
-0.15±0.14 |
0.630 |
0.188 |
0.874 |
0.960 |
| Free fatty acid (μEq/L) |
631.8±43.2 |
604.7±37.4 |
-27.1±53.9 |
542.2±34.7 |
631.9±43.0 |
89.8±44.0 |
0.098 |
0.658 |
0.669 |
0.170 |
| ApoA1 (g/dL) |
1.44±0.03 |
1.26±0.03† |
-0.18±0.03 |
1.45±0.04 |
1.31±0.03† |
-0.14±0.03 |
0.284 |
0.002 |
0.729 |
0.216 |
| ApoB(g/dL) |
0.87±0.03 |
0.70±0.03† |
-0.17±0.02 |
0.88±0.04 |
0.76±0.04† |
-0.12±0.02 |
0.049 |
0.001 |
0.540 |
0.025 |
| Atherosclerosis Indices |
|
|
|
|
|
|
|
|
|
|
| TC/HDL |
3.8±0.1 |
3.4±0.2 |
-0.42±0.2 |
3.9±0.2 |
3.8±0.2 |
-0.10±0.2 |
0.303 |
0.935 |
0.460 |
0.357 |
| LDL/HDL |
2.4±0.1 |
2.2±0.1 |
-0.25±0.1 |
2.5±0.2 |
2.3±0.2 |
-0.15±0.1 |
0.630 |
0.976 |
0.671 |
0.752 |
| (TC-HDL)/HDL |
2.8±0.1 |
2.5±0.2 |
-0.32±0.2 |
2.9±0.2 |
2.8±0.2 |
-0.04±0.03 |
0.253 |
0.975 |
0.454 |
0.297 |
| ApoB/ApoA1 | 0.61±0.02 | 0.56±0.03† | -0.05±0.01 | 0.61±0.03 | 0.60±0.03 | -0.01±0.02 | 0.296 | 0.075 | 0.240 | 0.593 |
All values are expressed as means ± SE.
HDL High-density lipoprotein cholesterol, LDL Low-density lipoprotein cholesterol, ApoA1 Apolipoprotein A1, ApoB Apolipoprotein B, TC/HDL total cholesterol/high density lipoprotein cholesterol ratio, LDL/HDL low density lipoprotein/cholesterol high density lipoprotein cholesterol ratio, (TC-HDL)/HDL (total cholesterol - high density lipoprotein cholesterol)/high density lipoprotein cholesterol ratio;
ApoB/ApoA1 Apolipoprotein B/Apolipoprotein A1.
P value1, t-test between changes of the Kocujinag and placebo group : P value2,3,4 time, group and interaction (time*group) effect of two-way repeated measure ANOVA, after adjusting for age and gender.
* Change = 12 –wk – 0-wk.
† Paired t-test between 0-wk and 12-wk (P<0.05).